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ABSTRACT
Background: Hepatitis C virus (HCV) infection occursin 0% to 51% of dialysis patients, 
and manyHCV-positive patients are urged to undergo kidney transplantation. How-
ever, the outcome of renal transplantation in HCV-positive recipients is unknown.
Objectives: Our review aimed to address the outcomesof renal transplantation recipi-
ents (RTRs)following kidney transplantation.
Materials and Methods: We selected studies that used the adjusted relative risk (aRR) 
and 95% CI of all-cause mortality and graft loss in HCV-positive compared with HCV-
negative RTRs as study endpoints. Cox proportional hazard analysis was usedin all 
studies to calculate the independent effects of HCV infection on RTR outcomes. Six-
teen retrospective cohort studies and 2 clinical trials were selected for our review. Six-
teen studies were related to patient survival, and 12 examined graft survival.
Results: The combined hazard ratio in HCV-infected recipients was 1.69-fold (1.33-1.97, 
p < 0.0001) and 1.56 times (1.22-2.004, p < 0.0001) greaterthan that of HCV-negative 
recipients for mortality and graft loss, respectively.
Conclusions: Although HCV-infected RTRs have worse outcomes than HCV-negative 
RTRs,kidney transplantation is the preferred treatment for patients with HCV infec-
tion and end-stage renal disease.
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Background
Hepatitis C virus (HCV) infection is a common problem 
among dialysis patients and kidney transplant recipients 
(1). The Centers for Disease Control and Prevention (CDC)
detects HCV infection by enzyme linked immunosorbent 
  Implication for health policy/practice/research/medical education: 
HCV infection may negatively interfere on final outcomes of kidney transplantation. We strongly recommend reading this interest-
ing article to all general practitioners, surgeons, nephrologists and urologists.
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assay (ELISA) in 8.1% (range 0% to 51%) of ESRD patients 
in large dialysis centers (2). Additionally, manyHCV-pos-
itivepatients  are  urged  to  undergokidney  transplanta-
tion (3). The major cause of mortality due to liver failure 
in kidney transplant recipients is HCV infection (4). The 
outcome of renal transplantation in HCV-positive recipi-
ents is unknown (2, 5); some studies havereported better 
survival in HCV-positive ESRD patients compared with 
those remaining on dialysis (1, 4, 6, 7).
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HCV-positive kidney transplant recipients was suggested 
to be a significant cause of pooroutcome (1, 4, 6,8). Also, 
viral  load  and  liver  deterioration  are  related  (8).  Con-
versely, several surveys did not observe worse outcomes 
in HCV-positive renal transplant recipients (RTRs) when 
HCV infection was acquired before kidney transplanta-
tion, especially during the first 5-8 years (7).
However, a recent study from a US registry evaluated 
the effect of immunosuppressive regimens on survival 
in HCV-positive RTRs, demonstrating that antibody in-
duction doesnot adversely affect patient survival (1, 7,9). 
Moreover, cyclosporine (10) and my cophenolat mofetil 
(MMF) may have protective effects (1, 6) and inhibit HCV 
replication in renal transplant patients with HCV infec-
tion.  Whether  hepatitis  virus  infected-patients  should 
stay on dialysis or be referred for kidney transplantation 
remains unknown. 
Objectives
We performed a meta-analysis to determine the effects 
of HCV infection on outcomes in RT patients.
Materials and Methods
Search strategy
We searched electronic databases, including PubMed, 
the Cochrane Database of Systematic Reviews, EMBASE, 
and CINHAL, for studies from Jan 1981 to Jan 2010 to iden-
tify those that reported the effect of HCV infection on RTR 
outcomes.  Our  keywords  included  “hepatitis  C,”  “HCV 
infection,”  “kidney  transplantation,”  “graft  survival,” 
“patients  survival,”  “mortality,”  “natural  history,”  “out-
come,” and their synonyms. Two authors independently 
developed a search strategy to identify randomized trials 
and cohort studies that investigated the effect of HCV on 
patients and graft survival after kidney transplantation. 
To  identify  additional  relevant  articles,  reference  lists 
from qualitative topic reviews and the identified articles 
were also searched. Duplicate publications were discard-
ed. We restricted our search to human studies and placed 
no restrictions on language. 
Study Selection
The  electronic  and  manual  searches  yielded  1137  pa-
pers by title and abstract, of which 149 were considered 
relevant and selected for a full text review. 131 irrelevant 
reports were excluded (Figure 1). After a full text review, 
16 retrospective cohort studies (1, 11-25), and 2 clinical tri-
als (26, 27) were selected for our review (Table 1). Sixteen 
studies were related to patient survival, and 12 examined 
graft survival. Study characteristics are summarized in 
Table 1.
Criteria for inclusion
Two independent reviewers assessed with a standard 
method  each  included  trial  about  adult  kidney  trans-
plant  recipients  with  HCV  infection,  defined  astesting 
positive for anti-HCV or HCV RNA by polymerase chain 
reaction (PCR) in serum at the time of enrollment. Also 
participants were evaluated with regard to patient and 
kidney  outcomes,  which  were  defined  as  liver-related 
death and return to dialysis due to HCV infection. Dis-
crepancies were resolved in conference. Other criteria for 
inclusion were controlled trials and cohort studies that 
reported patient and graft survival among HCV-infected 
RTRs. Table 1 shows the characteristics of the studies in 
this review. Studies that included HCV-infected donors 
were excluded. Between the trials included in our meta-
analysis, there are a few differences in patients and graft 
outcome (Table 2). Thus, we decided to pool these data for 
evaluation.
Review questions and endpoints of interest
Our review aimed to answer two specific questions:
1. What is the effect of HCV infection on renal graft sur-
vival?
2. What is the effect of HCV infection on renal recipient 
survival?
All selected studies used the adjusted relative risk (aRR) 
and 95% CI of all-cause mortality and graft loss in HCV-
positive versus -negative RTRs as study endpoints. Cox 
proportional hazard 5) (we have converted HR to RR with 
a  formula)  analysis  was  usedin  all  studiesto  calculate 
independent effects of HCV infection on RTR outcomes 
after  adjustments  for  potentially  contributing  factors, 
such as age, gender, follow-up period, type of transplant, 
diabetes  mellitus,  post-transplant  plasma  creatinine, 
race, duration of dialysis, donor death etiology, and pro-
teinuria.First-generation enzyme-linked immunoadsor-
bent assay test before 1991, second generation until 1997 
and third generation until now were used to detect HCV 
Figure 1. Summary of literature search and study selectionHepat Mon. 2011;11(4):247-254
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infection. Further, serum HCVRNA (PCR) was examined 
in anti-HCV-positive patients for confirmation of HCV in-
fection in 6 studies. 
Statistical analysis
We pooled outcomes (mortality rates, renal allograft 
failure), which had been expressed as relative risk (RR) 
with 95% confidence intervals (CI), using STATA 8. The re-
sults of each outcome were analyzed for heterogeneity 
by Q test (the random effects method of Der Simonian-
Laird). Funnel plots, Begg's rank correlation test, and Eg-
ger's regression asymmetry test were used to assess the 
existence of publication bias. The Forest plot was used to 
demonstrate the details of pooled analysis. Combined 
hazard ratios were assessed by sensitivity analysis. 
Results
Description of Included Trials
The included studies are summarized in Table 1. Follow 
up duration and adjusted variables for each study shown 
in table 2 and adjusted relative risk for mortality and graft 
loss also presented in table 3. A total of 8348 HCV-infected 
RTRs before or after kidney transplantation were identi-
fiedfrom 123,228 living and deceased RTRs, asreported in 
18 studies. Pereira BJ et al. had 2 studiesin different years. 
Data on 8 studies (Pereira BJ et al. study 1, Pereira BJ et al. 
study 2, Legendre C et al., Gentil MA et al., Lee WC et al., 
Breitenfeldt et al., Bruchfeld et al., and Morales et al.) that 
were reported before 2005 were also used in a meta-anal-
ysis by Fabrizi et al. and Gentil MA et al. confirmed HCV 
infection detection by immunoblotting, and Bruchfeld 
(71%), Ridruejo (33.54%), Ingsathit (100%), Mitwalli (100%), 
  Table 1. Study characteristics
Authors country
Number of all patients/
HCV+ RTRs
Patient/graft survival 
reports (Yes/No)
Type of Study 
Einollahi et al.
(2003) (11)
Iran 1006/45 Yes/yes Retrospective cohort
Luan et al.
(2008) (1)
U.S 79337/3708 Yes/no Retrospective cohort
Aroldi et al.
(2005) (12)
Italy 541/209 Yes/yes Retrospective cohort
Legendre et al.
(1998) (13)
France 499/112 Yes/no Retrospective cohort
Gentil et al.
(1999) (14)
Spain 320/85 Yes/yes Retrospective cohort
Lee et al.
(2001) (15)
Taiwan 477/136 Yes/yes Retrospective cohort
Breitenfeldt et al.
(2002) (16)
Germany 927/123 Yes/yes Retrospective cohort
Bruchfeld et al.
(2004) (17)
Sweden 571/51 Yes/no Retrospective cohort
Morales et al.
(2004) (18)
Spain 3365/488 Yes/yes Retrospective cohort
Ingsathit et al.
(2007) (19)
Thailand 346/22 Yes/no Retrospective cohort
Batty et al.
(2001) (20)
 U.S 28692/1624 Yes/no Retrospective cohort
Mahmoud et al.
(2004) (21)
Egypt 133/80 Yes/yes Retrospective cohort
Lin et al.
(2004) (22)
Taiwan 299/129 Yes/yes Retrospective cohort
Ridruejo et al.
(2007) (23)
Argentina 396/155 Yes/yes Retrospective cohort
Gentil Govantes et al.
(2009) (24)
Spain  5693/1053 No/yes Retrospective cohort
Mitwalli et al.
(2006) (25)
Saudi Arabia 448/286 No/yes Retrospective cohort
Pereira et al.
(1995) (26)
U.S 75/19 Yes/yes Clinical trial
Pereira et al.
(1998) (27)
U.S 103/23 Yes/yes Clinical trialHepat Mon. 2011;11(4):247-254
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and  Mahmoud  (100%)  of  hemodialysis  patients  con-
firmed it by HCV-RNA (PCR). In response to our request, 
Einollahi et al. replied that nearly 70% of HCV positive an-
tibody anti HCV antibody positive RTRs were confirmed 
by HCV RNA (PCR).
Effect on patient and graft survival
The Q-test for heterogeneity revealed p < 0.0001 (Q = 
69.81, df = 15) and p < 0.0001 (Q = 66.15, df = 11) for patient 
and graft survival, respectively. Further, a meta-analysis 
was  done  with  a  random  model  showed  a  combined 
hazard ratio in HCV-infected recipients that was 1.69-fold 
(1.33-1.97, p < 0.0001) (Figure 2) and 1.56 times ( 1.22-2.004, 
p < 0.0001) (Figure 3) greaterthan in HCV-negative recipi-
ents for mortality and graft loss, respectively.
Authors year Adjusted variables
Einollahi et al. 
(2003) (11)
1995-2001 Donor characteristic (age, source, gender, blood group) and recipient characteristic 
(age, gender, ESRD etiology, history of diabetes, blood group)
Luan et al.
(2008) (1)
1995-2004 Recipient characteristics (age, sex, race, diabetes, renal diagnosis,time on dialysis, panel 
reactive antibody level, availability of private insurance) and donor characteristics (age, 
living donor, extended criteria donor, cold ischemia time, presence of hypertension, 
creatinine level, and cause of death)
Aroldi et al.
(2005)(12)
1972-1989 age
Gentil et al.
(1999) (14)
1986-1997 Donor characteristic (age, gender, time on dialysis, ESRD etiology, number of transplant, 
pre-transplant transfusion, peak and immediate pre-transplant immunization, number 
of HLA A+B and HLA DR mismatches, years of transplant, cold ischemia time, anti HCV 
Ab, pre-transplant clinical liver disease
Lee et al.
(2001) (15)
1984-1999 Sex, mode of dialysis, duration of dialysis, diabetes, hypertension, HBV infection, HCV 
infection, liver function impairment, hepatoma
Breitenfeldt et al.
(2002) (16)
1978-1994 HBeAg, HCV infection after transplantation, con-comitant HBV and HCV infection, occur-
rence of acute rejection, age at transplantation and time on dialysis, HBeAg positivity, 
HBsAg positivity, HCV infection after transplantation, age at transplantation and occur-
rence of acute rejection.
Bruchfeld et al.
(2004) (17)
1989-1997 age, sex, diabetes, previous transplantations, type of transplant, and time in RRT for 
death, HCV, diabetes
Moraleset al.
(2004) (18)
1990-1994 year of transplant, recipient age, Last panel reactive antibodies, acute rejection, trigly-
cerides, Creatinine, proteinurea
Ingsathit et al.
(2001) (19)
3.7 year acute rejection episode, recipient age, long duration of dialysis; diabetes mellitus, 
delayed graft function, and sex mismatch, Creatinine
Batty et al.
(2001) (20)
1994-1997 age, race, gender, end-stage renal disease due to diabetes, weight, year of transplant, 
duration of pre-transplant dialysis, previous transplant, donor and recipient age, donor 
and recipient race, donor and recipient gender, delayed graft function, antibody induc-
tion therapy (combined and also analyzed separately for OKT3 and ALG), and allograft 
rejection
Mahmoud et al.
(2004) (21)
1993-1995 donor and recipient age and sex, primary cause of ESRD, HLA mismatch, number of 
transplants, time on dialysis therapy, number of acute rejection episodes, presence of 
persistent proteinuria, and year of transplantation.
Lin et al.
(2004) (22)
1981-2000 Recipient age and sex, donor age and sex, anti HCV Ab, chronic hepatitis, pre-transplant 
diabetes, , pre-transplant hypertension, pre-transplant coronary artery disease, HLA  DR 
mismatch
Ridruejo et al.
(2007) (23)
1991-2004 Age,  anti-HCV, traditional immunosuppression, rejection
Gentil Govantes et al.
(2009) (24)
1984-1989
1990–1995
1996–2001
2002–2007
sex and age of the recipient, diabetes as ESRD cause, retransplant status, duration of 
previous RRT, and transplant year, Transplant time period
Mitwalli et al.
(2006) (25)
1980-2001 age, sex, blood pressure, type of donor, and immunosuppressive medication , type of 
donor (living related, living unrelated, and cadaver donors), hepatitis status, hepatitis-
positive or hepatitis-negative
Pereira et al.
(1998) (27)
1987-1990 Effects of hepatitis C infection and renal transplantation on survival in end-stage renal 
disease. The New England Organ Bank Hepatitis C Study Group
Table 2. Follow up and adjusting variables of included articlesHepat Mon. 2011;11(4):247-254
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Publication bias
For patient and graft survival rates, publication bias was 
examined  using  Bagg  and  Manzumdarand  Egger’s  re-
gression asymmetry, both of which were non-significant 
[(p = 0.753, p = 0.226; Figure 4) and (p = 0.304, p = 0.55; 
Figure 5), respectively]. Similar results were observed in 
the funnel plots.
Sensitivity analysis
All eligible studies included in meta-analysis. Because 
the elimination of each study did not have an impact on 
the combined hazard ratio, the overall estimation was 
robust (Figure 6). 
Discussion
Hepatitis C infection is a risk factor for graft loss and 
death in renal transplant recipients (8). Although our 
report  and  recent  studies  have  emphasized  the  detri-
mental role of hepatitis C in long-term patient and graft 
survival after renal transplantation (10), several studies 
have demonstrated that patient and graft survival on-
Figure 2. Hazard ratio in HCV-infected recipients for patient survival
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Figure 3. Hazard ratio in HCV-infected recipients for graft survival
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HCV infection after renal transplantation arethe same in 
the shortterm compared withnon-infected renal trans-
plant  patients  (6).  Conversely,  kidney  transplantation 
is a better option for HCV-positive ESRD patients versus 
remaining on dialysis (1).To better examineHCV-positive 
RTR outcomes, we performed a meta-analysis using ob-
servational studies that used adjusted data of all-cause 
mortality.
Impact on patient survival
Consistent  withFabrizi’s  meta-analysis,  the  aRR  for 
mortality rate in our study was lower than inother stud-
ies (4, 8, 13, 14, 17), likely due to the greater sample size, 
early detection, improvement in management, and ex-
act  follow-up.  Compared  with  Fabrizi’s  meta-analysis, 
which included 8 articles, our study included 18 articles 
that comprisedmore than 123,000 RTRs, indicatingthat 
greaterconsideration has been given to the controversy 
of  HCV-infected  RTR  outcomes  and  kidney  transplan-
tation in the past5 years. Several studies have demon-
strated lower patient and graft survival in HCV-positive 
RTRs, related in part to associated complications, such as 
cirrhosis, hepatocellular carcinoma, cardiovascular dis-
ease, diabetes mellitus, sepsis, higher PRA, and deceased 
kidney donation (1, 10).
Impact on graft survival:
In our study,the aRR for graft loss was similar to that 
in Fabrizi’s meta-analysis. Although during the first 5-10 
years, graft and patient survival was apparently similar 
between  negative  and  positive  HCV-infected  RTRs  (4), 
HCV-associated  glomerulonephritis,  proteinuria,  and 
diabetic nephropathy can progressrapidly to chronic al-
lograft nephropathy (6).
Role of other factors in mortality
It  appears  that  the  increased  mortality  in  anti-HCV-
positive patients was partially related to mortality dueto 
causes other than HCV infection. According to a novel 
risk score for mortality in RTRs (29), the risk score for HCV 
(1.5) was not more than age above 40 years in comparison 
to younger than 40  (2.2-6.7), pre-transplant diabetes mel-
litus (1.8), post-transplant diabetes mellitus (1.5), serum 
creatinine levels at the first year after transplantation 
(1.7), and proteinuria greater than 1g during the first year 
of operation (2.7). In a recent meta-analysis, mortality 
due to liver complications, such as cirrhosis and hepato-
cellular carcinoma, among HCV-infected RTRs increased 
in  most  studiesthat  were  included,  with  anRRof  1.79, 
compared with HCV-negative recipients (6). In a system-
atic review, cardiovascular and infectious diseases were 
also important causes of death in HCV-positive RTRs (6).
Because mortality and graft loss are multifactorial, we 
used the aRR that had been obtained by the Cox regres-
sion model in each study to appraise the isolated influ-
ence of HCV infection on patient and graft survival. In 
contrast to studies that reported a negative impact, the 
majority of studies that demonstrated a positive impact 
of transplantation on HCV-infected patient and graft sur-
vival rates did not use the Cox regression model; conse-
quently, studies that observed a positive impact or not 
on HCV-positive patients were excluded from this sys-
tematic review and meta-analysis. Although our study 
and other similar articles on the effect of HCV infection 
on patient and graft survival did not have any publica-
tion bias, it appears that we included only papers with 
a negative impact (Figure 2, 3).Consistent with previous 
surveys, we observed that the aRR of all-cause mortality 
and graft failure was significantly higher for seropositive 
a N.A.: Not Accessible
Author
95% confidence interval
a RR for mortality a RR for graft loss
Einollahi et al.
(2003) (11)
4.308 (2.88-6.4) 2.609 (2.07-3.27)
Luan et al.
(2008) (1)
1.3 (1.2-1.4) N.A.a
Aroldi et al.
(2005) (12)
1.65 (1.13-2.42) 1.4 (1.17-1.81)
Pereira et al.
(1995) (26)
1 (0.49-2.02) 0.95 (0.54-1.67)
Pereira et al.
(1998) (27)
2.6 (1.15-5.9) 1.3 (0.66-2.58)
Legendre et al.
(1998) (13)
2.8 (1.4-5.7) N.A.a
Gentil et al.
(1999) (14)
3.1 (1.2-7.8) 3 (1.8-5)
Lee et al.
(2001) (15)
1.57 (0.75-1.11) 1.25 (0.75-1.32)
Breitenfeldt et al.
(2002) (16)
1.93 (1.01-3.42) N.A.a
Bruchfeld etal.
(2004) (17)
2.23 (1.48-3.34) 1.96 (1.37-2.79)
Morales et al.
(2004) (18)
1.505 (1.12-2.02) 1.58 (1.27-1.97)
Ingsathit et al.
(2007) (19)
1.59 (0.28-9.02) N.A.a
Batty et al.
(2001) (20)
1.23 (1.01-1.49) N.A.a
Mahmoud et al.
(2004) (21) 
0.5 (0.1-1.9) 0.5 (0.3-1.2)
lin et al.
(2004) (22)
0.3 (0.13-0.65) 0.8 (0.48-1.35)
Ridruejo et al.
(2007) (23)
1.66 (1.01-2.77) 1.97 (1.18-3.29)
Gentil Govantes 
et al.
(2009) (28)
N.A.a 1.5 (1.1-1.9)
Mitwalli et al.
(2006) (25)
N.A.a 4.37 (1.8-4.8)
Table 3. Adjusted relative risk for mortality and graft lossHepat Mon. 2011;11(4):247-254
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HCV recipients after kidney transplantation.
Role  of  immunosuppression  in  HCV-positive  kidney 
transplant recipients
The progression of liver failure in HCV-positive RTRs fol-
lowing immunosuppression is debated. While previous 
studies have illustrated a detrimental effect on liver func-
tion in these patients (10, 11), more recent studies have 
observed relatively slow development of liver fibrosis in 
such patients (1). Luan (2008) performed a study using 
national  data  and  Cox  regression  analysis  to  estimate 
hazard ratios, adjusted for donor, recipient, and trans-
plant variables. A total of 3708 HCV-positive and 75,629 
HCV-negative kidney transplant recipients were includ-
ed,  wherein  no  calcineurin  inhibitors  (cyclosporine  A 
or tacrolimus) or steroids had a significant impact on 
patient mortality. Moreover, the use of mycophenolyte-
mofetile (MMF) not only was associated with a signifi-
cantly reduction in mortality rate, it also had a protec-
tive effect (1), despite it sassociation with increased HCV 
viremia(1). According to another study, HCV replication 
increases after kidney transplantation, likely due to im-
munosuppression  (1).  In  contrast,  in  cultured  hepato-
cytes, cyclosporine A, but not tacrolimus, prevents HCV 
replication.  Notably,  more  than  50%  of  HCV-positive 
kidney  transplant  recipients  who  are  treated  with  cy-
closporine  A  have  stable  liver  function  and  decreased 
liver  fibrosis  (1).  Nevertheless,  in  HCV-positive  kidney 
transplant patients, the use of antibody induction has 
no correlation with viral load (1) and does not have a 
negative influence on patient survival in these patients 
(6). It appears that the anti-HCV activity of cyclosporine 
A differs from its immunosuppressive effects (10). Thus, 
based on the protective effects of new immunosuppres-
sive drugs, such as MMF and cyclosporine, we hope for 
greater survival of HCV-positive renal transplant recipi-
ents. Yet, controversy still exists regarding the impact of 
HCV infection on the outcomes of renal transplantation.
Limitations
The  majority  of  articles  are  not  complete;  some  did 
not  consider  Cox  regression,  and  the  aRR  for  patient 
and graft survival was not reported. Some contributing 
factors, such as alcohol or drug consumption, were not 
noted. After renal transplantation, HCV-positive patients 
have  lower patient and graft survival rates compared 
with HCV-negative patients. However, HCV infection is 
not  a  contraindication  for  renal  transplantation;  and 
HCV therapy before transplantation is important to im-
prove the outcome of the patients after transplantation.
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